MJ
Therapeutic Areas
Axsome Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Auvelity (AXS-05) | Major Depressive Disorder (MDD) | Approved |
| Sunosi (solriamfetol) | Narcolepsy / Obstructive Sleep Apnea (OSA) | Approved |
| Symbravo (AXS-07) | Migraine | Approved |
| AXS-12 | Narcolepsy (Cataplexy) | Phase 3 |
| AXS-14 | Fibromyalgia | Phase 3 |
Leadership Team at Axsome Therapeutics
HT
Herriot Tabuteau, MD
Chief Executive Officer, Founder, Chairman
NP
Nick Pizzie, CPA, MBA
Chief Financial Officer
HM
Hunter Murdock, Esq.
General Counsel
AM
Ari Maizel
Chief Commercial Officer
MC
Mark Coleman, MD
Director
RJ
Roger Jeffs, PhD
Director
SM
Susan Mahony, PhD, MBA
Director